PTC Therapeutics Plunges 16% Despite Positive PIVOT-HD Study Results

On May 5, 2025, Ptc Therapeutics experienced a significant drop of 16% in pre-market trading, marking a notable decline in its stock performance.

PTC Therapeutics recently announced that its PIVOT-HD study for the drug PTC518 achieved its primary endpoint, demonstrating a significant reduction in blood Huntingtin (HTT) protein levels at 12 weeks. This result indicates that PTC518 effectively lowers HTT protein levels, which is a key goal in treating Huntington's disease. The study also showed early signs of clinical benefit with a favorable safety profile, suggesting that the drug may have potential as a treatment for this debilitating condition.

The positive results from the PIVOT-HD study have been well-received by the medical community, as they provide hope for a new therapeutic option for patients with Huntington's disease. The study's success in achieving its primary endpoint and demonstrating a favorable safety profile has generated optimism about the future of PTC518 as a potential treatment for this disease.